Parallax Volatility Advisers
CUE icon

Parallax Volatility Advisers’s Cue Biopharma CUE Stock Holding History

Parallax Volatility Advisers’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,500
Closed -$268K – 2487
2023
Q1 		$268K Hold
2,500
– – ﹤0.01% 1920
2022
Q4 		$214K Hold
2,500
– – ﹤0.01% 2118
2022
Q3 		$167K Hold
2,500
– – ﹤0.01% 2365
2022
Q2 		$187K Sell
2,500
-24
-1% -$2.81K ﹤0.01% 2220
2022
Q1 		$369K Buy
+2,524
New +$535K ﹤0.01% 2010

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Parallax Volatility Advisers's CUE Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Cue Biopharma (CUE) in Q2 2023, closing a stake of 2,500 shares — an estimated $268K sold.

Parallax Volatility Advisers first reported a position in CUE in Q1 2022 and held it in 5 quarters. The position peaked at $369K in Q1 2022. 78 funds tracked by Wall St. Rank hold CUE as of Q2 2023.

  • Parallax Volatility Advisers reported no remaining Cue Biopharma position as of Q2 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,500 Cue Biopharma shares in Q2 2023, an estimated $268K.
  • Parallax Volatility Advisers first reported a position in Cue Biopharma in Q1 2022 and held it in 5 quarters.
  • Parallax Volatility Advisers's Cue Biopharma position peaked at $369K in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.